Rotterdam, The Netherlands (24 April 2025) – IMCD N.V. ("IMCD" or "Company"), a global leading partner for the distribution and formulation of speciality chemicals and ingredients, today announces that IMCD and Valerie Diele-Braun have agreed that Valerie will step down as CEO and member of the Management Board for personal reasons. This change takes effect as of today. The Supervisory Board is pleased to announce that Marcus Jordan will assume the role of CEO as of today. Marcus is a member of the Manageme ...

Haffner Energy unveils Hynoca® Flex 500 IG: A flexible, cost-effective alternative to grey hydrogen and fossil fuels Cogeneration of hydrogen and electricity offers a unique solution for managing random hydrogen demand Vitry-le-François, France – April 24, 2025, 08:00am (CET) Haffner Energy introduces Hynoca® Flex 500 IG, a line of hydrogen production units capable of producing 12 tonnes of green hydrogen per day to be delivered under €3/kg without subsidies. Hynoca®Flex 500 IG also enables the production o ...

Strasbourg, France, April 24, 2025, 8:00 a.m. CET - Transgene (Euronext Paris: TNG), a biotech company that designs and develops virus-based immunotherapies, announced that the documentation related to the Combined General Meeting (ordinary and extraordinary sessions) of Transgene’s shareholders is available. The notice of meeting, comprising the agenda and the draft resolutions, was published in the Bulletin des Annonces Légales Obligatoires (BALO) n° 42 of April 7, 2025 and in the corrigendum no. 47 of Ap ...

Core Insights - Orange reported strong first-quarter results for 2025, achieving revenues of €9,911 million, a 0.6% increase year-on-year, and confirmed its financial targets for the year [1][6][11] - The company's EBITDAaL grew by 3.2% to €2,480 million, reflecting solid retail performance and operational efficiency improvements [8][41] - The Africa & Middle East region was a significant growth driver, with revenues increasing by 12.8% to €2,047 million, supported by strong mobile data and digital service offerings [21][22] Financial Performance - Total revenues for Q1 2025 reached €9,911 million, up from €9,849 million in Q1 2024, driven by retail services growth of 2.4% [1][5] - EBITDAaL for the quarter was €2,480 million, marking a 3.2% increase compared to €2,402 million in the previous year [8][41] - eCAPEX for the quarter was €1,463 million, a 6.6% increase from €1,372 million in Q1 2024 [8][41] Regional Performance - In France, revenues decreased by 1.3% to €4,297 million, but retail services excluding PSTN grew by 1.5% [15][16] - The Africa & Middle East region saw exceptional growth, with mobile data revenues up 21.0% and Orange Money revenues up 22.1% [21][22] - Europe remained stable with revenues of €1,746 million, a slight decrease of 0.2%, while retail services grew by 2.5% [24][25] Business Segments - Orange Cyberdefense reported solid growth of 8% in the B2B market, primarily driven by performance in France [4] - The Orange Business segment experienced a revenue decline of 4.9% to €1,851 million, impacted by lower fixed-only and mobile revenues [28] - TOTEM, the TowerCo, achieved revenues of €178 million, up 2.5% year-on-year, with a tenancy ratio of 1.43 co-tenants per site [30][31] Strategic Developments - The company signed three agreements with trade unions in France to enhance employment and career path planning, focusing on training and recruitment [5] - MASORANGE, the joint venture in Spain, reported a 2.6% revenue increase and achieved significant synergies, targeting over €300 million in synergies for 2025 [34][36][37]

Leadership Transition - Mike Kuehnel will not seek re-election as CEO for another full term at the 2025 AGM and will leave Flow Traders at the end of August 2025 to pursue a new opportunity [4][5] - The Board has initiated a search for Kuehnel's successor while he has agreed to be nominated for re-election at the upcoming AGM [5] - Marc Jansen will be nominated for election as Executive Director at the AGM and will serve a term of four years if approved [18] New Appointments - Marc Jansen and Alex Kieft have been appointed as Co-Chief Trading Officers, effective immediately, to jointly manage the Global Trading Division [6][14] - Both Jansen and Kieft have extensive experience within the company, with Jansen having joined in 2013 and Kieft in 2014 [10][11] Company Performance and Strategy - Under Kuehnel's leadership, Flow Traders launched the Trading Capital Expansion Plan in 2024, contributing to the firm's second-best financial year in its 20-year history [8][13] - The firm has focused on enhancing efficiency through automation and building a scalable organization, while also developing a global leadership team [9][12] - The company aims to intensify efforts in both traditional and digital asset markets as part of its long-term growth strategy [14]

Core Insights - Huhtamaki Oyj reported stable financial performance in Q1 2025 despite a volatile market environment, with net sales remaining at EUR 1,002 million, a slight decrease of 0% compared to Q1 2024 [5][12] - The company achieved adjusted EBITDA of EUR 152 million, reflecting a 2% increase year-over-year, and reported EBIT increased by 21% to EUR 94 million [2][19] - The company is focused on efficiency improvements and has achieved EUR 87 million in cost savings as part of its ongoing efficiency program [7][22] Financial Performance - Net sales for Q1 2025 were EUR 1,001.6 million, compared to EUR 1,003.9 million in Q1 2024, indicating a 0% change [2][5] - Comparable net sales growth was -2% at the Group level, with notable declines in Foodservice Packaging and Flexible Packaging [12][14] - Adjusted EPS increased by 7% to EUR 0.59, while reported EPS rose significantly by 57% to EUR 0.54 [2][19] Segment Performance - Foodservice Packaging saw a 3% decline in sales, while North America remained stable with 0% change [12][14] - Fiber Packaging delivered strong growth with a 13% increase in sales, contributing positively to the overall performance [12][14] - Adjusted EBIT for Fiber Packaging increased by 43%, while Foodservice Packaging and North America experienced declines of 10% and 15%, respectively [15][16] Cost Management and Efficiency - The company has implemented a three-year program aimed at achieving EUR 100 million in cost savings, with EUR 87 million already realized by the end of Q1 2025 [21][22] - Program-related costs accounted for EUR 25 million, including benefits from divesting real estate in China [22] - The company continues to focus on disciplined capital allocation and accountability to enhance operational efficiency [9][10] Market Outlook - The trading conditions for 2025 are expected to remain stable, allowing the company to pursue profitable growth opportunities [23] - Increased market uncertainty due to geopolitical events has led to cautious behavior among customers and consumers [6][11] - The company is actively monitoring market developments and adapting its strategies accordingly [11]

Core Insights - The company reported a Q1 sales growth of 9.7% at constant exchange rates (CER) and a business EPS of €1.79, indicating a strong start to 2025 [1][3][8] Sales Performance - Pharma launches generated sales of €0.8 billion, reflecting a 43.8% increase, primarily driven by ALTUVIIIO [6] - Dupixent sales reached €3.5 billion, up 20.3%, while vaccine sales amounted to €1.3 billion, up 11.4% due to favorable phasing of Beyfortus [6] - Total IFRS net sales were reported at €9,895 million, representing a 10.8% increase [8] Financial Metrics - Business EPS increased by 17.0% reported and 15.7% at CER, reaching €1.79 [6][8] - IFRS net income rose by 65.2% to €1,872 million, with IFRS EPS reported at €1.52, up 67.0% [8] - Free cash flow was reported at €1,029 million [8] Pipeline and Approvals - The company achieved six regulatory approvals across various therapeutic areas, including immunology, rare diseases, and oncology [6][5] - Significant progress was noted in the pipeline, with new data from mid-stage studies unlocking late-stage studies in asthma and skin diseases [6][5] Capital Allocation and Strategy - The company confirmed its capital allocation strategy, including a share buyback program of €5 billion, with 72% already repurchased [7][4] - The anticipated closing of the sale of a controlling stake in Opella is expected in Q2 [7] Future Outlook - Sales are projected to grow by a mid-to-high single-digit percentage at CER in 2025, with business EPS expected to increase at a low double-digit percentage at CER before share buyback [7]

Core Points - Eramet reported stable adjusted turnover of €742 million in Q1 2025, reflecting a mixed operating performance amid a challenging market environment [3][19][90] - The company maintained its operational targets for 2025 despite geopolitical tensions and market uncertainties [4][31] - Safety performance improved significantly, with a Total Recordable Incident Rate (TRIR) of 0.6, a 30% reduction compared to Q1 2024 [5] Financial Performance - Adjusted turnover remained stable compared to Q1 2024, with a negative volume/mix effect of -5% offset by positive price and currency effects of +3% each [7][19] - Manganese activities turnover increased by 2% to €457 million, while nickel turnover decreased by 18% to €114 million [15][36] - Mineral Sands turnover rose by 30% to €68 million, driven by increased production volumes [54] Production and Sales - Nickel ore production in Indonesia increased by 3% to 9.2 million wet metric tons (Mwmt), but external sales volumes decreased by 11% due to temporary destocking [35][45] - Manganese ore external sales fell by 15% to 1.2 million tons, impacted by operational difficulties at the port of Owendo [20][27] - First sales of lithium carbonate were achieved in Argentina, confirming the operational efficiency of the Direct Lithium Extraction (DLE) technology [4][63] Market Trends - The global market for manganese ore remains uncertain, with a consensus price of around $4.7/dmtu for 2025 [25][32] - Demand for nickel is expected to grow, driven by stainless steel production, while the market remains in slight surplus [48][49] - The lithium market is projected to remain under pressure due to increased supply, despite strong demand from electric vehicle sales [73][74] Strategic Initiatives - The company is focused on maintaining a controlled capital expenditure plan of €400 million to €450 million for 2025 [3][88] - Eramet's sustainability initiatives include the launch of the eraLow brand for low CO2 manganese alloys and the publication of its first Sustainability Report [9][8] - The Ageli project in Alsace has been recognized as a strategic project, facilitating support for its development [76][77]

Group 1 - Meriaura Group Plc is proposing the election of Jussi Mälkiä to the Board of Directors due to Samuli Koskela's unavailability [1][2] - The revised proposal includes the re-election of Antti Veh-viläinen and Jussi Mälkiä, along with new members Arto Räty, Sirpa-Helena Sormunen, and Erja Sankari [3] - All proposed board members, except Jussi Mälkiä, are independent of the company and significant shareholders [4] Group 2 - Meriaura Group operates in two business areas: Marine Logistics and Renewable Energy [4] - The Marine Logistics segment is a major provider of transport for bulk cargo and project deliveries in Northern Europe, focusing on low-emission marine transport services [5] - VG-EcoFuel Oy, part of the Marine Logistics business, produces biofuels from industrial by-products [6] Group 3 - The Renewable Energy business designs and delivers clean energy production systems, including large-scale solar thermal systems [7] - Rasol Oy, part of the Renewable Energy segment, provides solar power systems for various applications [7] - Meriaura Group's shares are listed on Nasdaq First North Growth Market in Sweden and Finland [8]

Core Viewpoint - ONWARD Medical N.V. has established a sponsored Level 1 American Depositary Receipt (ADR) program in the United States, facilitating trading for US investors following FDA clearance and commercial launch of its ARC-EX System [2][3][4] Group 1: ADR Program and Trading - The ADR program allows US institutional investors to trade ONWARD Medical's shares in US dollars, enhancing accessibility for those interested in the company's growth [3][4] - The ADRs are now trading on the OTCQX Best Market under the ticker symbol ONWRY, with one ADR representing one ordinary share of ONWARD [2][4] - The partnership with Bank of New York Mellon (BNY) as the depositary bank is expected to improve stock liquidity and broaden the shareholder base [3][4] Group 2: Company Overview and Technology - ONWARD Medical focuses on innovative spinal cord stimulation therapies aimed at restoring movement and independence for individuals with spinal cord injuries and other movement disabilities [2][7] - The company has developed ARC Therapy, which has received ten Breakthrough Device Designations from the FDA, and the ARC-EX System is cleared for commercial sale in the US [7] - ONWARD is also working on an investigational implantable system called ARC-IM, which may include a brain-computer interface [7][8] Group 3: Market Presence and Future Engagement - The establishment of the ADR program and the upgrade to OTCQX is seen as a significant milestone for ONWARD Medical, enhancing its presence in the US market [4] - The company aims to engage with the spinal cord injury community to develop solutions that restore movement and function [5][7] - US investors can access financial disclosures and real-time quotes through the OTC Markets website, further facilitating investment opportunities [5]